The number of breast carcinoma patients has been increasing in Japan. We usually consider the possibility of international comparison studies with western countries, because the incidence of breast cancers among women in these countries is much more frequent than in Japan. Previously, however, there have been few opportunities to compare our data with those from other Asian countries or to characterize the breast lesions of Asian women other than those in Japan. …
Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.